title: Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain.
abstract: Agomelatine is a melatonergic MT1/MT2 agonist and a serotonin (5-HT) 5-HT(2C) antagonist. The effects of 2-day and 14-day administration of agomelatine were investigated on the activity of ventral tegmental area (VTA) dopamine (DA), locus coeruleus (LC) norepinephrine (NE), and dorsal raphe nucleus (DRN) 5-HT neurons using in vivo electrophysiology in rats. The 5-HT(1A) transmission was assessed at hippocampus CA3 pyramidal neurons. After a 2-day regimen of agomelatine (40 mg/kg/day, i.p.), an increase in the number of spontaneously active VTA-DA neurons (p<0.001) and in the firing rate of LC-NE neurons (p<0.001) was observed. After 14 days, the administration of agomelatine induced an increase in: (1) the number of spontaneously active DA neurons (p<0.05), (2) the bursting activity of DA neurons (bursts/min, p<0.01 and percentage of spikes occurring in bursts, p<0.05), (3) the firing rate of DRN-5-HT neurons (p<0.05), and (4) the tonic activation of postsynaptic 5-HT(1A) receptors located in the hippocampus. The increase in 5-HT firing rate was D2 dependent, as it was antagonized by the D2 receptor antagonist paliperidone. The enhancement of NE firing was restored by the 5-HT(2A) receptor antagonist MDL-100,907 after the 14-day regimen. All the effects of agomelatine were antagonized by a single administration of the melatonergic antagonist S22153 (except for the increase in the percentage of spikes occurring in burst for DA neurons). The present results suggest that (1) agomelatine exerts direct (2 days) and indirect (14 days) modulations of monoaminergic neuronal activity and (2) the melatonergic agonistic activity of agomelatine contributes to the enhancement of DA and 5-HT neurotransmission.
authors.affiliation: Institute of Mental Health Research, University of Ottawa, Ottawa, ON, Canada.
authors.forename: Franck
authors.initials: F
authors.lastname: Chenu
authors.forename: Mostafa
authors.initials: M
authors.lastname: El Mansari
authors.forename: Pierre
authors.initials: P
authors.lastname: Blier
mesh_terms: D000081:Acetamides / Q000008:administration & dosage*; D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000502:physiology*; D004298:Dopamine / Q000502:physiology*; D055724:Electrophysiological Phenomena / Q000187:drug effects / Q000502:physiology; D008297:Male; D008550:Melatonin / Q000819:agonists* / Q000037:antagonists & inhibitors / Q000502:physiology; D009638:Norepinephrine / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D044094:Receptors, Melatonin / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology; D012701:Serotonin / Q000502:physiology*; D013876:Thiophenes / Q000494:pharmacology; D009281:Naphthalenes
chemical_list: D000081:Acetamides; D004298:Dopamine; D008550:Melatonin; D009638:Norepinephrine; D044094:Receptors, Melatonin; D012701:Serotonin; D013876:Thiophenes; C120267:S 22153; C084711:agomelatine; D009281:Naphthalenes